RUSSIA : Russia’s consumer health watchdog Rospotrebnadzor told local media that the COVID-19 vaccine, known as the second-registered EpiVacCorona in Russia, had proved to be “100 percent effective” in early trials.
Data based on Phase I and Phase II experiments were released before the start of the large Phase III experiment, which typically involved thousands of participants and a placebo group as a comparison.
The first and second phase studies looked at the potential vaccine safety, immunity, and immunization potential of 100 people between the ages of 18 and 60, according to the State Case Registry.
Russia began testing the EpiVacCorona, developed by the Siberian Vector Institute, in November.
Earlier that month, Moscow said its other approved vaccine, Sputnik V, was 92 percent effective in protecting people against COVID – 19.
Russia says it can vaccinate 60 percent of its population against COVID-19 this year, and although the Sputnik V vaccine is readily available in Moscow, its spread across the country has slowed.
Russian President Vladimir Putin has ordered a major injection from this week.
Russia has reported 3,612,800 cases of coronavirus, the fourth highest in the world.
The death toll from the virus is 66,623.Leave a comment